FDMT Stock Forecast & Price Target

4D Molecular Therapeutics is viewed favorably because 4D-150 has shown durable efficacy, safety, and a meaningful reduction in treatment burden in wet AMD, including 78% overall burden reduction over 2 years in PRISM and 87% in recently diagnosed patients. The company’s Phase 3 4FRONT program is already de-risked by completed enrollment, with 4FRONT-2 finishing about 4 months ahead of initial projections and the primary endpoint focused on Week 52 non-inferiority in mean BCVA versus aflibercept. With a current -$750M market cap and -$360M EV, the market appears to underappreciate the path to >$1B peak 4D-150 revenue by 2033 if pivotal data continue to validate the therapy.

4D Molecular Therapeutics is burdened by substantial fundamental risk because its gene therapy portfolio remains early in development while the field is already crowded, increasing the odds of clinical, regulatory, and commercial setbacks. The company’s lead programs, including 4D-150 for wet AMD and DME, still face uncertainty around study outcomes, payer acceptance in an elderly population, and whether Medicare will support a therapy with roughly a 5 year benefit horizon. It also appears likely to need additional capital to fund operations, and failure to achieve peak commercial revenue estimates or advance programs successfully could meaningfully weaken the investment case.